0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A cytotoxic survey on 2‐amino‐1H‐imidazol based synthetic marine sponge alkaloid analogues

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Here, we describe the synthesis and biologic activity evaluation of 20 novel synthetic marine sponge alkaloid analogues with 2‐amino‐1H‐imidazol (2‐AI) core. Cytotoxicity was tested on murine 4T1 breast cancer, A549 human lung cancer, and HL‐60 human myeloid leukemia cells by the resazurin assay. A total of 18 of 20 compounds showed cytotoxic effect on the cancer cell lines with different potential. Viability of healthy human fibroblasts and peripheral blood mononuclear cells upon treatment was less hampered compared to cancer cell lines supporting tumor cell specific cytotoxicity of our compounds. The most cytotoxic compounds resulted the following IC 50 values 28: 2.91 µM on HL‐60 cells, and 29: 3.1 µM on 4T1 cells. The A549 cells were less sensitive to the treatments with IC 50 15 µM for both 28 and 29. Flow cytometry demonstrated the apoptotic effect of the most active seven compounds inducing phosphatidylserine exposure and sub‐G1 fragmentation of nuclear DNA. Cell cycle arrest was also observed. Four compounds caused depolarization of the mitochondrial membrane potential as an early event of apoptosis. Two lead compounds inhibited tumor growth in vivo in the 4T1 triple negative breast cancer and A549 human lung adenocarcinoma xenograft models. Novel marine sponge alkaloid analogues are demonstrated as potential anticancer agents for further development.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Principles of early drug discovery.

            Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of $1 billion. The idea for a target can come from a variety of sources including academic and clinical research and from the commercial sector. It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery programme. Once a target has been chosen, the pharmaceutical industry and more recently some academic centres have streamlined a number of early processes to identify molecules which possess suitable characteristics to make acceptable drugs. This review will look at key preclinical stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate molecule for clinical development. © 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

              Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration (FDA) in 2001, an increasing number of small-molecule targeted drugs have been developed for the treatment of malignancies. By December 2020, 89 small-molecule targeted antitumor drugs have been approved by the US FDA and the National Medical Products Administration (NMPA) of China. Despite great progress, small-molecule targeted anti-cancer drugs still face many challenges, such as a low response rate and drug resistance. To better promote the development of targeted anti-cancer drugs, we conducted a comprehensive review of small-molecule targeted anti-cancer drugs according to the target classification. We present all the approved drugs as well as important drug candidates in clinical trials for each target, discuss the current challenges, and provide insights and perspectives for the research and development of anti-cancer drugs.
                Bookmark

                Author and article information

                Contributors
                i.kanizsai@avidinbiotech.com
                szebeni.gabor@brc.hu
                Journal
                Drug Dev Res
                Drug Dev Res
                10.1002/(ISSN)1098-2299
                DDR
                Drug Development Research
                John Wiley and Sons Inc. (Hoboken )
                0272-4391
                1098-2299
                02 November 2022
                December 2022
                : 83
                : 8 ( doiID: 10.1002/ddr.v83.8 )
                : 1906-1922
                Affiliations
                [ 1 ] Laboratory of Functional Genomics Biological Research Centre Szeged Hungary
                [ 2 ] PhD School in Biology University of Szeged Szeged Hungary
                [ 3 ] Avidin Ltd Szeged Hungary
                [ 4 ] Department of Dermatology and Allergology University of Szeged Szeged Hungary
                [ 5 ] Department of Physiology, Anatomy, and Neuroscience, Faculty of Science and Informatics University of Szeged Szeged Hungary
                Author notes
                [*] [* ] Correspondence Gábor J. Szebeni, Laboratory of Functional Genomics, Biological Research Centre, Temesvari krt. 62, Szeged H6726, Hungary.

                Email: szebeni.gabor@ 123456brc.hu

                Iván Kanizsai, Avidin Ltd., Alsó kikötő sor 11/D, Szeged H6726, Hungary.

                Email: i.kanizsai@ 123456avidinbiotech.com

                Author information
                https://orcid.org/0000-0003-0109-7097
                https://orcid.org/0000-0002-6998-5632
                Article
                DDR22006
                10.1002/ddr.22006
                10091778
                36322473
                d9e18cb1-2b26-4c28-9dba-0a769fa47309
                © 2022 The Authors. Drug Development Research published by Wiley Periodicals LLC.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 23 September 2022
                : 21 July 2022
                : 12 October 2022
                Page count
                Figures: 10, Tables: 1, Pages: 17, Words: 10315
                Funding
                Funded by: 2020‐1.1.6‐JÖVO‐2021‐00003
                Funded by: National Research, Development, and Innovation Office (NKFI), Hungary
                Funded by: ÚNKP‐22‐5 ‐SZTE‐535 (GJS) New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund
                Funded by: János Bolyai Research Scholarship of the Hungarian Academy of Sciences BO/00582/22/8
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                December 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.7 mode:remove_FC converted:12.04.2023

                Pharmacology & Pharmaceutical medicine
                2‐amino‐(1h)‐imidazole,4t1 breast cancer,a549 lung cancer,hl‐60 myeloid leukemia,mannich

                Comments

                Comment on this article